Integrating minimal residual disease monitoring into clinical practice for NSCLC: Is the era upon us?

Abstract

In this issue of Cancer Cell, Chen etal. and Pan etal. employ personalized, tumor-informed technology to detect minimal residual disease in non-small-cell lung cancer and demonstrate the clinical promise of integrating liquid biopsy techniques to improve the assessment of cancer progression and metastasis risk.